|
|
|
20.11.26 - 14:00
|
Moog Inc. Delivers Record Fiscal 2026 Results; Guides Another Strong Year for Fiscal 2027 (Business Wire)
|
|
|
EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. (NYSE: MOG.A and MOG.B), a worldwide designer, manufacturer and systems integrator of high-performance precision motion and fluid controls and control systems, today reported record fiscal 2026 results for sales, adjusted segment operating margin, adjusted diluted net earnings per share and free cash flow, along with a strong fiscal fourth quarter.
“Fiscal 2026 was a milestone year for the company. We delivered record results and achieved the goals we established at our 2023 Investor Day," said Pat Roche, CEO. "These results reflect our employees' dedication to improving how we operate and better serving our customers. I'm proud of what we accomplished in our 75th anniversary year and confident in our ability to deliver sustained, profitable growth and long-term value creation."
(in millions, except per share results)
Three Months Ended
Twelve Months Ended
October 3,2026
September 27,2025
Deltas
October 3,2026
September 27,2025
Deltas
Net...
|
|
|
|
|
18.11.26 - 18:03
|
Biocom Welcomes Zachary Hornby of Callio Therapeutics and Kevin Marks of Parker Institute to Board of Directors (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--#boardofdirectors--Biocom, the largest life science membership association, representing companies across California and major life science markets worldwide, today announced the appointment of Zachary Hornby, chief executive officer of Callio Therapeutics, and Kevin Marks, chief legal officer of Parker Institute to its board of directors.“Zach and Kevin have each helped turn breakthrough science into real companies and real treatments, and they are exactly the kind of leaders Biocom needs at a pivotal moment for our industry,” said Tim Scott, president and CEO of Biocom. “Zach has taken companies from the lab to the public markets and helped lead Ignyta's $2 billion sale to Roche, while Kevin has spent decades guiding legal strategy across diagnostics, regenerative medicine and immunotherapy. Their judgment will sharpen how we serve our members as we grow across life science markets. We're fortunate to have them on our board....
|
|
|
|
|
|
|
17.11.26 - 20:12
|
Roche Underperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Roche nach einem Gespräch mit Finanzchef Alan Hippe einer hauseigenen Branchenkonferenz auf "Underperform" mit einem Kursziel von 250 Franken belassen. Dieser habe sich erfreut über die Giredestrant-Zulassung ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.11.26 - 08:36
|
Roche Outperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Roche auf "Outperform" mit einem Kursziel von 400 Franken belassen. Trung Huynh sieht die überraschend frühe Zulassung von Giredestrant in Brustkrebs-Kombinationstherapie positiv ......
|
|
|
|
|
|